Sarah G. Injac, MD

Nurix Therapeutics, Inc.

Poster(s):

• 1506 - Bexobrutideg (NX-5948), a novel Bruton’s tyrosine kinase (BTK) degrader, demonstrates rapid and durable clinical responses in relapsed/refractory CLL: updated findings from an ongoing Phase 1a study